- Taiwan
- /
- Hospitality
- /
- TWSE:8462
Power Wind Health Industry Full Year 2024 Earnings: EPS: NT$4.77 (vs NT$1.50 in FY 2023)
Power Wind Health Industry (TWSE:8462) Full Year 2024 Results
Key Financial Results
- Revenue: NT$5.12b (up 19% from FY 2023).
- Net income: NT$370.4m (up 230% from FY 2023).
- Profit margin: 7.2% (up from 2.6% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: NT$4.77 (up from NT$1.50 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Power Wind Health Industry shares are up 8.0% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Power Wind Health Industry that you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:8462
Power Wind Health Industry
Engages in the business of membership-based fitness center chains, leisure sports venues, and other sports services in Taiwan.
Outstanding track record, good value and pays a dividend.
Market Insights
Weekly Picks

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

EU#4 - Turning Heritage into the World’s Strongest Luxury Empire

The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story
Recently Updated Narratives

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Novo Nordisk - A Fundamental and Historical Valuation

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Popular Narratives

The "Sleeping Giant" Stumbles, Then Wakes Up
Undervalued Key Player in Magnets/Rare Earth

